^
    2d
    ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (clinicaltrials.gov)
    P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    2d
    A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=238, Active, not recruiting, Shanghai Miracogen Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    docetaxel • capecitabine • Meiyouheng (becotatug vedotin)
    3d
    A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=142, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • docetaxel • capecitabine
    3d
    SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, University of Miami | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    3d
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.
    New P2/3 trial
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin
    3d
    A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). (clinicaltrials.gov)
    P3, N=507, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb)
    3d
    An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma. (PubMed, ESMO Gastrointest Oncol)
    Patients will receive T-DXd (5.4 mg/kg, day 1) combined with nivolumab (360 mg/body, day 1) and CAPOX (capecitabine: 750 mg/m2 twice daily, days 1-14 and oxaliplatin: 70 mg/m2, day 1), every 3 weeks. Hypothesis testing assumes a null ORR of 58% and an alternative ORR of 80%. The planned sample size is 28 patients treated with RP2D.
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin
    3d
    GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. (PubMed, ESMO Gastrointest Oncol)
    One hundred and ninety-three patients with resected pancreatic ductal adenocarcinoma from the ESPAC-4 trial of adjuvant gemcitabine and capecitabine were included. GATA6 expression was not associated with differential treatment effects. GATA6 expression measured by immunohistochemistry with digital assistance was a prognostic biomarker among people with pancreatic adenocarcinoma treated with surgical resection and adjuvant chemotherapy.
    Journal
    |
    GATA6 (GATA Binding Protein 6)
    |
    gemcitabine • capecitabine
    3d
    Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery. (PubMed, Cancer Biother Radiopharm)
    Capecitabine and docetaxel administered via ultrasound improve therapeutic efficacy in advanced TNBC, lessen immune suppression brought on by treatment, improve quality of life, and support a positive safety profile while encouraging higher decreases in tumor marker expression. These results demonstrate the potential therapeutic benefit of using ultrasound-based medication delivery techniques into TNBC systemic therapy.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    cisplatin • docetaxel • capecitabine
    3d
    CCRT-AC-HRDM-NPC: Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients (clinicaltrials.gov)
    P3, N=294, Completed, Sun Yat-sen University | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • capecitabine
    4d
    A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 04] (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Nanjing Leads Biolabs Co.,Ltd
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    4d
    Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Enrolling by invitation, Peking University First Hospital
    New P2 trial
    |
    capecitabine • TheraCIM (nimotuzumab)